The primary objective of current research is extending healthspan—the period of time spent in good health—rather than focusing solely on increasing the maximum human lifespan.

• Rationale: Although human lifespan has increased significantly over the past decades, the healthspan has not increased at the same rate.

• The Goal: Researchers are testing compounds that have the potential to delay or reverse aging processes to optimise the healthspan by delaying the onset of aging-related diseases.

• Current Reality: There is currently no proven drug or supplement that extends human lifespan demonstrated in a long-term human randomised controlled trial. According to recent expert analysis, near-term increases of 10 or more years to the average human lifespan from single interventions are unlikely. Incremental improvements, such as adding months or a few years, may be achievable through combinations of interventions as research advances.

The Science of Longevity: Evidence-Based Interventions from Clinical Research

Welcome to "The Science of Longevity," a podcast dedicated to exploring the latest evidence-based research on aging, lifespan extension, and healthspan improvement. We move beyond speculation to analyze peer-reviewed clinical studies and rigorous scientific evidence published within the last decade.

Episode Focus: From Hallmarks to Human Trials

The field is currently at an exciting inflection point, with multiple human clinical trials underway targeting fundamental aging mechanisms, such as cellular senescence, mitochondrial dysfunction, NAD+ decline, and accumulated DNA damage.

What we cover in this episode:

• The Realistic Goal: We explore why the realistic promise of current longevity research is primarily extended healthspan—achieving more years of healthy, functional life and delaying the onset of aging-related diseases—rather than expecting dramatic lifespan increases in the near term. It is important to note that there is no proven drug or supplement that extends human lifespan demonstrated in a long-term human randomized controlled trial.
• Rapamycin and mTOR Inhibitors: Learn about the most studied potential longevity intervention, rapamycin, which inhibits the mTORC1 pathway. While every preclinical study has shown that rapamycin extends mouse lifespan in at least one dosing group, early human evidence suggests benefits for immune function.
• Metformin and Longevity Candidates: We discuss the observational evidence suggesting that longevity candidates like metformin and Vitamin D may significantly reduce all-cause mortality and prolong life expectancy. Metformin is currently being rigorously tested in the landmark Targeting Aging with Metformin (TAME) trial.
• Cellular Cleanup: Senolytics and NAD+ Boosters: We dive into interventions targeting cellular decline, including senolytics (like dasatinib combined with quercetin), which selectively eliminate senescent "zombie cells" implicated in frailty. Additionally, we review the robust human safety data on NAD+ precursors (NMN and nicotinamide riboside), which show efficacy for metabolic improvements and increased physical performance in older adults.
• Emerging Geroprotectors: Urolithin A: We review the evidence on Urolithin A (UA), a gut metabolite derived from foods like pomegranate and walnut, being assessed for its potential geroprotective effect in humans. Recent systematic reviews covering five studies involving 250 healthy individuals indicate that UA (10–1000 mg/day) showed a dose-dependent anti-inflammatory effect and increased muscle strength and endurance. However, UA did not affect physical function, anthropometrics, cardiovascular outcomes, or maximal ATP production in these studies.

Join us as we assess the efficacy, safety, and future directions of these promising interventions, providing you with evidence-informed insights into how to improve your healthspan.

Ever wonder what goes on behind the pharmacy counter? You might be shocked to learn that Artificial Intelligence is already transforming how we discover, dispense, and manage medications, making healthcare SAFER and SMARTER than ever before. In this video, we pull back the curtain on the cutting-edge AI and Machine Learning applications changing medicine right now, with real-world results from the world's most famous hospitals.

Forget science fiction—this is happening TODAY. We're talking about AI systems that can:

🔹 Slash dangerous medication errors by up to 80%

🔹 Predict harmful drug reactions with 65% better detection

🔹 Help create new life-saving drugs in record time

🔹 Fight the global crisis of antibiotic resistance

Join us as we explore the incredible case studies and jaw-dropping statistics that prove AI is the future of pharmacy.

---

⏱️ TIMESTAMPS:

0:00 - The AI Revolution in Your Medicine Cabinet

1:15 - Discovering New Drugs with AI: How companies like Atomwise and Insilico Medicine are using deep learning to find treatments for diseases like Ebola, fibrosis, and multiple sclerosis.

3:45 - REAL-LIFE AI MIRACLES: Case Studies from World-Leading Hospitals!

4:02 - Cleveland Clinic: Slashing hospital readmissions by 42% with an AI-powered system that also improved medication adherence by 35%.

5:30 - Mayo Clinic: Using predictive analytics to cut incorrect antibiotic prescriptions by 45% and reduce deadly C. difficile infections by 30%.

6:55 - Johns Hopkins: How a Machine Learning system predicts adverse drug reactions, reducing serious events by 48% and saving an estimated AUD $4.2 million annually.

8:21 - Singapore's Robot Pharmacy: An automated system that reduced medication dispensing errors by a staggering 75% and cut preparation time by 60%.

9:40 - The AI Triage Nurse: See how Australian pharmacies are using AI to cut patient wait times in half and improve referral accuracy by 65%.

11:05 - The Future is NOW: Quantum Computing & Beyond!

Discover how emerging tech like quantum computing could improve the prediction of protein-drug interactions by up to 300% and how federated learning is helping researchers collaborate while protecting patient data

This crash course provides the foundational knowledge needed to understand and implement effective outpatient pharmacy operations management and KPI systems. Success requires ongoing commitment to quality improvement, staff development, and patient-centered care delivery.

ASHP and ASHP Foundation Pharmacy Forecast 2025, a comprehensive report offering strategic planning guidance for pharmacy departments in hospitals and health systems. It examines critical issues impacting the pharmacy profession and healthcare landscape over the next five years, including the business of healthcare, managing ultra-high-cost drugs, addressing the primary care gap, implementing whole person health, navigating generative artificial intelligence, and stabilizing the pharmacy workforce. Based on a survey of pharmacy leaders, the forecast provides insights and recommendations to help organizations proactively address emerging trends and prepare for future challenges in patient care and medication management.